PICI Network in the News | Recent Highlights
Parker Institute for Cancer Immunotherapy
Our mission is to accelerate the development of breakthrough immune therapies to turn all cancers into curable diseases
The Parker Institute for Cancer Immunotherapy (PICI) is committed to turning all cancers into curable diseases faster, with a relentless focus on science, collaboration, patients and bold action. The PICI Network gives life to this pursuit, pushing novel immunotherapy research forward with partnerships, events, awards and individual accomplishments.?
Every month, we’ll round up PICI Network news to highlight collaborations between researchers, nonprofits and industry, highlighting the impact of our collective pursuits on the field.?
Read on for recent achievements.?
Network News & Research Advances?
PICI | July 27, 2022
Meet PICI's largest class of early career researchers yet, nine exceptional graduate and postdoctoral researchers from leading academic institutions.
Nature | July 19, 2022
Dozens of clinical trials, including one led by PICI Director of Informatics Christine Spencer, PhD, are taking aim at the cancer-microbiome connection.
University of California, San Francisco/Gladstone Institutes | July 11, 2022
The work by researchers at UCSF, Gladstone and Stanford has implications for developing immunotherapies and understanding autoimmune diseases. Alex Marson, MD, PhD, of Gladstone and UCSF is co-senior author of the study.
Stanford Medicine | July 11, 2022
Research led by Robbie Majzner, MD, of Stanford seeks to explain why dinutuximab doesn't help every patient.
领英推荐
Cancer Network | July 13, 2022
Robert Vonderheide, MD, DPhil, of Penn offers insights into data presented at ASCO that stem from long-term collaboration between academia, biotech, pharma and nonprofits.
Oncology Nursing News | July 13, 2022
At a 7.5-year follow-up, nivolumab-based treatment regimens continued to display superior overall survival rates, duration of response, and health-related quality of life compared with ipilimumab monotherapy, according to an analysis of CheckMate 067. Stephen Hodi, MD, of the Dana-Farber Cancer Institute, presented the data at ASCO.
Perspectives
El País | June 6, 2022
The Washington University School of Medicine researcher, who recently received an honorary degree from the University of Barcelona, discusses the history and continuing promise of immunotherapy.
Stanford Medicine | July 20, 2022
Vaccinology has taken great leaps forward in the past decade, largely due to advanced analytical methods as well as a shift in researchers’ focus from rodents to humans, the Stanford researcher explains.
Cell & Gene | July 28, 2022
Carl June, MD, of Penn discusses the past, present and future of CAR-T cell therapy and what's on the horizon for immunotherapy, on Cell & Gene: The Podcast.